Study of Aripiprazole in Patients With Bipolar I Disorder

NCT ID: NCT00257972

Last Updated: 2013-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bipolar Mania

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aripiprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of bipolar I disorder, manic or mixed episode

Exclusion Criteria

* First manic or mixed episode
* Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole
* Participation in a previous clinical trial within the past month or ever participated in a trial with aripiprazole
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka America Pharmaceutical

INDUSTRY

Sponsor Role collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution

Surbiton, Middlesex, United Kingdom

Site Status

Local Institution

Little Rock, Arkansas, United States

Site Status

Local Institution

Riverside, California, United States

Site Status

Local Institution

Deerfield Beach, Florida, United States

Site Status

Local Institution

Jacksonville, Florida, United States

Site Status

Local Institution

Maitland, Florida, United States

Site Status

Local Institution

Hoffman Estates, Illinois, United States

Site Status

Local Institution

Oak Brook, Illinois, United States

Site Status

Local Institution

Newton, Kansas, United States

Site Status

Local Institution

Newton, Massachusetts, United States

Site Status

Local Institution

New York, New York, United States

Site Status

Local Institution

Staten Island, New York, United States

Site Status

Local Institution

Raleigh, North Carolina, United States

Site Status

Local Institution

Dayton, Ohio, United States

Site Status

Local Institution

Media, Pennsylvania, United States

Site Status

Local Institution

Norristown, Pennsylvania, United States

Site Status

Local Institution

Philadelphia, Pennsylvania, United States

Site Status

Local Institution

Columbia, South Carolina, United States

Site Status

Local Institution

Memphis, Tennessee, United States

Site Status

Local Institution

Austin, Texas, United States

Site Status

Local Institution

Bellevue, Washington, United States

Site Status

Local Institution

Epping, Victoria, Australia

Site Status

Local Institution

Rousse, , Bulgaria

Site Status

Local Institution

Sofia, , Bulgaria

Site Status

Local Institution

Varna, , Bulgaria

Site Status

Local Institution

Brno - Bohunice, , Czechia

Site Status

Local Institution

Hradec Králové, , Czechia

Site Status

Local Institution

Opava, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Pärnu, , Estonia

Site Status

Local Institution

Tallinn, , Estonia

Site Status

Local Institution

Tartu, , Estonia

Site Status

Local Institution

Viljandi Maakond, , Estonia

Site Status

Local Institution

Voru Maakond, , Estonia

Site Status

Local Institution

Bordeaux, , France

Site Status

Local Institution

Dole, , France

Site Status

Local Institution

Grenoble, , France

Site Status

Local Institution

Jonzac, , France

Site Status

Local Institution

La Rochelle, , France

Site Status

Local Institution

Limoges, , France

Site Status

Local Institution

Marseille, , France

Site Status

Local Institution

Nîmes, , France

Site Status

Local Institution

Pessac, , France

Site Status

Local Institution

Rennes, , France

Site Status

Local Institution

Berlin, , Germany

Site Status

Local Institution

Jena, , Germany

Site Status

Local Institution

Magdeburg, , Germany

Site Status

Local Institution

Meunchen, , Germany

Site Status

Local Institution

Westersted, , Germany

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Gyula, , Hungary

Site Status

Local Institution

Kecskemét, , Hungary

Site Status

Local Institution

Nagykálló, , Hungary

Site Status

Local Institution

Bassano del Grappa, , Italy

Site Status

Local Institution

Cagliari, , Italy

Site Status

Local Institution

Florence, , Italy

Site Status

Local Institution

Pisa, , Italy

Site Status

Local Institution

Roma, , Italy

Site Status

Local Institution

Sassari, , Italy

Site Status

Local Institution

Trieste, , Italy

Site Status

Local Institution

Voghera -Pavia, , Italy

Site Status

Local Institution

Retranchement, , Netherlands

Site Status

Local Institution

Zaandam, , Netherlands

Site Status

Local Institution

Choroszcz, , Poland

Site Status

Local Institution

Kościan, , Poland

Site Status

Local Institution

Krakow, , Poland

Site Status

Local Institution

Poznan, , Poland

Site Status

Local Institution

Torun, , Poland

Site Status

Local Institution

Tuszyn, , Poland

Site Status

Local Institution

Lisbon, , Portugal

Site Status

Local Institution

Leningrad Region, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Smolensk, , Russia

Site Status

Local Institution

Port Elizabeth, Eastern Cape, South Africa

Site Status

Local Institution

Westdene, Free State, South Africa

Site Status

Local Institution

Pretoria, Gauteng, South Africa

Site Status

Local Institution

Vereeniging, Gauteng, South Africa

Site Status

Local Institution

Welkom, Gauteng, South Africa

Site Status

Local Institution

Durban, KwaZulu-Natal, South Africa

Site Status

Local Institution

Observatory, Western Cape, South Africa

Site Status

Local Institution

Barcelona, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Valencia, , Spain

Site Status

Local Institution

Vitoria-Gasteiz, , Spain

Site Status

Local Institution

Herisau, , Switzerland

Site Status

Local Institution

Glasgow, Dumbartonshire, United Kingdom

Site Status

Local Institution

London, Greater London, United Kingdom

Site Status

Local Institution

Burnley, Lancashire, United Kingdom

Site Status

Local Institution

South Wales, Mid Glamorgan, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway Sweden United States Australia Bulgaria Czechia Estonia France Germany Hungary Italy Netherlands Poland Portugal Russia South Africa Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, Owen R, Nameche L. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008 Oct;165(10):1316-25. doi: 10.1176/appi.ajp.2008.07101560. Epub 2008 Apr 1.

Reference Type BACKGROUND
PMID: 18381903 (View on PubMed)

Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010 Jun;26(6):1485-96. doi: 10.1185/03007991003779380.

Reference Type DERIVED
PMID: 20429835 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CN138-134

Identifier Type: -

Identifier Source: org_study_id